机构:[1]Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA[2]Department of Medicine, Harvard Medical School, Boston, MA, USA[3]Department of Diagnostics, School ofMedicine, Hangzhou Normal University, Hangzhou, China[4]Department of Medical Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, China昆明医科大学附属第一医院[5]Clinical LaboratoryDivision, Brigham and Women’s Hospital, Boston, MA, USA[6]Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA[7]Department of Immunology,Harvard Medical School, Boston, MA, USA[8]School of Medicine, University of California, San Francisco, San Francisco, CA, USA
Tumour-associated antigens (TAAs) comprise a large set of non-mutated cellular antigens recognized by T cells in human and murine cancers. Their potential as targets for immunotherapy has been explored for more than two decades(1), yet the origins of TAA-specific T cells remain unclear. While tumour cells may be an important source of TAAs for T cell priming(2), several recent studies suggest that infection with some viruses, including Epstein-Barr virus and influenza virus can elicit T cell responses against abnormally expressed cellular antigens that function as TAAs(3,4). However, the cellular and molecular basis of such responses remains undefined. Here we show that expression of the Epstein-Barr virus signalling protein LMP1 in B cells provokes T cell responses to multiple TAAs. LMP1 signalling leads to overexpression of many cellular antigens previously shown to be TAAs, their presentation on major histocompatibility complex classes I (MHC-I) and II (MHC-II) (mainly through the endogenous pathway) and the upregulation of costimulatory ligands CD70 and OX40L, thereby inducing potent cytotoxic CD4(+) and CD8(+) T cell responses. These findings delineate a mechanism of infection-induced anti-tumour immunity. Furthermore, by ectopically expressing LMP1 in tumour B cells from patients with cancer and thereby enabling them to prime T cells, we develop a general approach for rapid production of autologous cytotoxic CD4(+) T cells against a wide range of endogenous tumour antigens, such as TAAs and neoantigens, for treating B cell malignancies. This work stresses the need to revisit classical concepts concerning viral and tumour immunity, which will be critical to fully understand the impact of common infections on human health and to improve the rational design of immune approaches to treatment of cancers. Expression of the Epstein-Barr virus protein LMP1 in B cells increases expression of-and promotes T cell responses to-tumour-associated antigens, delineating a mechanism of infection-induced anti-tumour immunity, which could inform immune-based approaches to cancer treatment.
基金:
NCI Cancer Center Support GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [NIH 5P30CA06516]; DFCI Faculty Startup Funds; Medical Oncology Translational Grant; Claudia Adams Barr Award; American Cancer SocietyAmerican Cancer Society [RSG-19-035-01-LIB]; Leukemia and Lymphoma SocietyLeukemia and Lymphoma Society [TRP-6595-20]; Wade F.B. Thompson/Cancer Research Institute CLIP Grant; Claudia Adams Barr Program for Innovative Cancer Research; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01CA206978-01]
第一作者机构:[1]Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA[2]Department of Medicine, Harvard Medical School, Boston, MA, USA
共同第一作者:
通讯作者:
通讯机构:[1]Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA[2]Department of Medicine, Harvard Medical School, Boston, MA, USA[6]Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
推荐引用方式(GB/T 7714):
Choi Il-Kyu,Wang Zhe,Ke Qiang,et al.Mechanism of EBV inducing anti-tumour immunity and its therapeutic use[J].NATURE.2020,doi:10.1038/s41586-020-03075-w.
APA:
Choi, Il-Kyu,Wang, Zhe,Ke, Qiang,Hong, Min,Paul, Dereck W., Jr....&Zhang, Baochun.(2020).Mechanism of EBV inducing anti-tumour immunity and its therapeutic use.NATURE,,
MLA:
Choi, Il-Kyu,et al."Mechanism of EBV inducing anti-tumour immunity and its therapeutic use".NATURE .(2020)